2018 Asembia Recap

Idiopathic pulmonary fibrosis (IPF) remains difficult to diagnose and manage because of its unknown etiology, varied clinical course, associated comorbidities, and nonspecific respiratory symptoms.

Results from research show that nearly 30% of Americans 40 years and older use a prescription medication to control their cholesterol and that 83% of that population use statins.

The number of treatment options available for psoriasis (PsO) and psoriatic arthritis (PsA) has significantly increased in the past decade and can provide patients with multiple modalities for efficacious symptom treatment, according to a continuing education symposium presented at the Asembia Specialty Pharmacy Summit 2018.

This symposium traced the evolution of immunoglobulin therapy from this inception to the state-of-the-art intravenous immunoglobulin products currently employed to manage a wide range of immune disorders.

A symposium presented at the Asembia Specialty Pharmacy Summit 2018 provided pharmacists a review of guideline-based RA management strategies, along with recent trial data on new and emerging agents.

As industry leaders converged on the largest annual conference focused on specialty pharmacy, issues surrounding value dominated the conversations at the Asembia Specialty Pharmacy Summit 2018.